Baker Bros. Advisors’s Adaptimmune Therapeutics ADAP Stock Holding History

Baker Bros. Advisors’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2,343,695	Closed	-$2.28M	–	94
2024 Q2	$2.28M	Sell	2,343,695 -8,443,327	-78%	-$9.27M	0.03%	78
2024 Q1	$17M	Sell	10,787,022 -182,260	-2%	-$220K	0.21%	41
2023 Q4	$8.7M	Hold	10,969,282	–	–	0.1%	51
2023 Q3	$8.56M	Hold	10,969,282	–	–	0.05%	48
2023 Q2	$10.1M	Buy	10,969,282 +1,138,405	+12%	+$1.36M	0.06%	55
2023 Q1	$10.7M	Hold	9,830,877	–	–	0.06%	52
2022 Q4	$14.4M	Hold	9,830,877	–	–	0.09%	50
2022 Q3	$10.6M	Hold	9,830,877	–	–	0.07%	62
2022 Q2	$16.7M	Hold	9,830,877	–	–	0.09%	55
2022 Q1	$20.3M	Hold	9,830,877	–	–	0.12%	52
2021 Q4	$36.9M	Hold	9,830,877	–	–	0.18%	43
2021 Q3	$50.8M	Hold	9,830,877	–	–	0.22%	35
2021 Q2	$41.9M	Hold	9,830,877	–	–	0.18%	42
2021 Q1	$52.2M	Hold	9,830,877	–	–	0.23%	38
2020 Q4	$53M	Buy	9,830,877 +3,500,523	+55%	+$19M	0.2%	33
2020 Q3	$50.5M	Sell	6,330,354 -344,827	-5%	-$3.02M	0.2%	32
2020 Q2	$66.8M	Buy	6,675,181 +2,984,874	+81%	+$18.7M	0.29%	27
2020 Q1	$10M	Buy	+3,690,307	New	+$12.2M	0.06%	49
2018 Q3	–	Sell	-100,000	Closed	-$1.19M	–	99
2018 Q2	$1.19M	Hold	100,000	–	–	0.01%	104
2018 Q1	$1.12M	Hold	100,000	–	–	0.01%	100
2017 Q4	$668K	Hold	100,000	–	–	0.01%	111
2017 Q3	$819K	Hold	100,000	–	–	0.01%	108
2017 Q2	$449K	Hold	100,000	–	–	﹤0.01%	115
2017 Q1	$551K	Hold	100,000	–	–	﹤0.01%	110
2016 Q4	$405K	Hold	100,000	–	–	﹤0.01%	123
2016 Q3	$705K	Hold	100,000	–	–	0.01%	120
2016 Q2	$815K	Hold	100,000	–	–	0.01%	119
2016 Q1	$813K	Hold	100,000	–	–	0.01%	118
2015 Q4	$1.21M	Hold	100,000	–	–	0.01%	117
2015 Q3	$1.2M	Hold	100,000	–	–	0.01%	115
2015 Q2	$1.83M	Buy	+100,000	New	+$1.72M	0.02%	104

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Baker Bros. Advisors's ADAP Position: Q3 2024 in Review

Baker Bros. Advisors sold out of Adaptimmune Therapeutics (ADAP) in Q3 2024, closing a stake of 2,343,695 shares — an estimated $2.28M sold.

Baker Bros. Advisors first reported a position in ADAP in Q2 2015 and held it in 31 quarters. The position peaked at $66.8M in Q2 2020. 81 funds tracked by Wall St. Rank hold ADAP as of Q3 2024.

Baker Bros. Advisors reported no remaining Adaptimmune Therapeutics position as of Q3 2024 after selling out during the quarter.
Baker Bros. Advisors sold 2,343,695 Adaptimmune Therapeutics shares in Q3 2024, an estimated $2.28M.
Baker Bros. Advisors first reported a position in Adaptimmune Therapeutics in Q2 2015 and held it in 31 quarters.
Baker Bros. Advisors's Adaptimmune Therapeutics position peaked at $66.8M in Q2 2020.
81 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2024.

Based on Baker Bros. Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.